3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Oxaliplatin
166
Capecitabine
112
Fluorouracil
95
Docetaxel
85
Cisplatin
84
S 1 (combination)
83
Leucovorin
64
Paclitaxel
58
Irinotecan
56
pembrolizumab
36
sintilimab
34
Trastuzumab
34
apatinib
30
Bevacizumab
21
Surgical Procedures, Operative
19
Radiotherapy
19
titanium silicide
17
camrelizumab
17
Nivolumab
17
Ramucirumab
16
Drug Therapy
15
Hyperthermic Intraperitoneal Chemotherapy
14
Folfox protocol
14
Epirubicin
14
tislelizumab
13
Neoadjuvant Therapy
12
Cetuximab
12
XELOX
10
Tegafur
10
Carboplatin
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Stomach Neoplasms
×
matuzumab
×
Clear all
NCT00215644
2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
72 enrolled
7 charts